A Pharmacological Batch of Mongersen that Downregulates Smad7 is Effective as Induction Therapy in Active Crohn’s Disease: A Phase II, Open-Label Study

BACKGROUND: A recent phase III trial did not confirm the previous clinical and endoscopic improvements seen in patients with Crohn’s disease (CD) receiving Mongersen, an oral Smad7 antisense oligonucleotide. Factors accounting for such a discrepancy are unknown. OBJECTIVE: Our objective was to furth...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:BioDrugs
Päätekijät: Marafini, Irene, Stolfi, Carmine, Troncone, Edoardo, Lolli, Elisabetta, Onali, Sara, Paoluzi, Omero Alessandro, Fantini, Massimo C., Biancone, Livia, Calabrese, Emma, Di Grazia, Antonio, Monteleone, Ivan, Lenti, Marco Vincenzo, Di Sabatino, Antonio, Monteleone, Giovanni
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Springer International Publishing 2021
Aiheet:
Original Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC8084825/
https://ncbi.nlm.nih.gov/pubmed/33871807
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40259-021-00482-x
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia